Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma

NARecruitingINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

September 10, 2019

Primary Completion Date

December 31, 2023

Study Completion Date

November 30, 2026

Conditions
Gastric Adenocarcinoma
Interventions
DRUG

Paclitaxel (albumin-bound) combined with Oxaliplatin and S-1

Paclitaxel (albumin-bound) : 150 mg/m2, iv,d1. S-1 : 40\~60mg,bid, d1-14( BSA\<1.25m2,40mg;1.25m2≤BSA≤1.5m2,50mg;BSA\>1.5m2,60mg) Oxaliplatin: 85mg/m2, iv, d1. Twenty-one days per cycle, a total of four cycles, after two cycles of treatment, the tumor was evaluated. The clinical efficacy was evaluated as CR\\PR\\SD and decided by the investigator to continue the treatment for two cycles or directly.

Trial Locations (1)

Unknown

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Peking University Cancer Hospital & Institute

OTHER